Kerrick / iStockphoto.com
A proposal in the North American Free Trade Agreement (NAFTA) to set the length of biologic data exclusivity at ten years would harm patients, according to generic associations.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Biosimilar, biologics, generic drugs, branded drugs, North American Free Trade Agreement, drug pricing, affordable drugs, access to medicine